San Diego, CA -- (SBWIRE) -- 11/09/2016 -- The Shareholders Foundation announced that an investor, who purchased shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), filed a lawsuit in California over alleged violations of Federal Securities Laws by Teva Pharmaceutical Industries Ltd in connection with certain allegedly false and misleading statements made between February 10, 2015 and November 3, 2016.

Investors who purchased shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) have certain options and for certain investors are short and strict deadlines running. Deadline: January 5, 2017. NYSE:TEVA investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The plaintiff claims that between February 10, 2015 and November 3, 2016 the Defendants made false and/or misleading statements and/or failed to disclose that Teva Pharmaceutical Industries Ltd was engaging and/or had engaged in conduct that would result in an antitrust investigation by the U.S. Department of Justice ("DOJ") and the State of Connecticut Office of the Attorney General, that the DOJ investigation and the underlying conduct could cause U.S. prosecutors to file criminal charges against Teva Pharmaceutical Industries Ltd by the end of 2016 for suspected price collusion, that in turn, Teva Pharmaceutical Industries Ltd lacked effective internal controls over financial reporting, and that as a result, Teva Pharmaceutical Industries' public statements were materially false and misleading at all relevant times.

According to news reports, United States prosecutors may file criminal charges against Teva Pharmaceutical Industries Ltd and others by the end of 2016 for suspected price collusion. It was has reported that the "antitrust investigation by the Justice Department, begun about two years ago, now spans more than a dozen companies and about two dozen drugs, according to people familiar with the matter. The grand jury probe is examining whether some executives agreed with one another to raise prices, and the first charges could emerge by the end of the year, they said." The companies identified as targets or relevant parties in the United States investigation include Mylan NV, Teva Pharmaceutical Industries Ltd, Allergan Plc, Lannett Co., Impax Laboratories Inc., Sun Pharmaceutical Industries Ltd., Mayne Pharma Group Ltd., Endo International Plc and Taro Pharmaceutical Industries Ltd.

Shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) declined to as low as $37.82 per share on November 3, 2016.

Those who purchased shares of Teva Pharmaceutical Industries Ltd (ADR) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com